Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

In Vitro Kinetic Characterization of Axitinib Metabolism.

Zientek MA, Goosen TC, Tseng E, Lin J, Bauman JN, Walker GS, Kang P, Jiang Y, Freiwald S, Neul D, Smith BJ.

Drug Metab Dispos. 2016 Jan;44(1):102-14. doi: 10.1124/dmd.115.065615. Epub 2015 Oct 28.

PMID:
26512042
2.

Biosynthesis of drug metabolites and quantitation using NMR spectroscopy for use in pharmacologic and drug metabolism studies.

Walker GS, Bauman JN, Ryder TF, Smith EB, Spracklin DK, Obach RS.

Drug Metab Dispos. 2014 Oct;42(10):1627-39. doi: 10.1124/dmd.114.059204. Epub 2014 Jul 22.

PMID:
25053618
3.

Undesired versus designed enzymatic cleavage of linkers for liver targeting.

Chirapu SR, Bauman JN, Eng H, Goosen TC, Strelevitz TJ, Sinha SC, Dow RL, Finn MG.

Bioorg Med Chem Lett. 2014 Feb 15;24(4):1144-7. doi: 10.1016/j.bmcl.2013.12.126. Epub 2014 Jan 8.

4.

Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitors.

Walsky RL, Bauman JN, Bourcier K, Giddens G, Lapham K, Negahban A, Ryder TF, Obach RS, Hyland R, Goosen TC.

Drug Metab Dispos. 2012 May;40(5):1051-65. doi: 10.1124/dmd.111.043117. Epub 2012 Feb 22.

PMID:
22357286
5.

On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds.

White TR, Renzelman CM, Rand AC, Rezai T, McEwen CM, Gelev VM, Turner RA, Linington RG, Leung SS, Kalgutkar AS, Bauman JN, Zhang Y, Liras S, Price DA, Mathiowetz AM, Jacobson MP, Lokey RS.

Nat Chem Biol. 2011 Sep 25;7(11):810-7. doi: 10.1038/nchembio.664.

6.

Metabolism-guided design of short-acting calcium-sensing receptor antagonists.

Southers JA, Bauman JN, Price DA, Humphries PS, Balan G, Sagal JF, Maurer TS, Zhang Y, Oliver R, Herr M, Healy DR, Li M, Kapinos B, Fate GD, Riccardi KA, Paralkar VM, Brown TA, Kalgutkar AS.

ACS Med Chem Lett. 2010 May 13;1(5):219-23. doi: 10.1021/ml100058w. eCollection 2010 Aug 12.

7.

Discovery tactics to mitigate toxicity risks due to reactive metabolite formation with 2-(2-hydroxyaryl)-5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3h)-one derivatives, potent calcium-sensing receptor antagonists and clinical candidate(s) for the treatment of osteoporosis.

Kalgutkar AS, Griffith DA, Ryder T, Sun H, Miao Z, Bauman JN, Didiuk MT, Frederick KS, Zhao SX, Prakash C, Soglia JR, Bagley SW, Bechle BM, Kelley RM, Dirico K, Zawistoski M, Li J, Oliver R, Guzman-Perez A, Liu KK, Walker DP, Benbow JW, Morris J.

Chem Res Toxicol. 2010 Jun 21;23(6):1115-26. doi: 10.1021/tx100137n.

PMID:
20507089
8.

Utility of the carboxylesterase inhibitor bis-para-nitrophenylphosphate (BNPP) in the plasma unbound fraction determination for a hydrolytically unstable amide derivative and agonist of the TGR5 receptor.

Eng H, Niosi M, McDonald TS, Wolford A, Chen Y, Simila ST, Bauman JN, Warmus J, Kalgutkar AS.

Xenobiotica. 2010 Jun;40(6):369-80. doi: 10.3109/00498251003706598.

PMID:
20297923
9.

Biochemical basis for differences in metabolism-dependent genotoxicity by two diazinylpiperazine-based 5-HT2C receptor agonists.

Kalgutkar AS, Bauman JN, McClure KF, Aubrecht J, Cortina SR, Paralkar J.

Bioorg Med Chem Lett. 2009 Mar 15;19(6):1559-63. doi: 10.1016/j.bmcl.2009.02.032. Epub 2009 Feb 12.

PMID:
19246199
10.

Utility of MetaSite in improving metabolic stability of the neutral indomethacin amide derivative and selective cyclooxygenase-2 inhibitor 2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)-N-phenethyl-acetamide.

Boyer D, Bauman JN, Walker DP, Kapinos B, Karki K, Kalgutkar AS.

Drug Metab Dispos. 2009 May;37(5):999-1008. doi: 10.1124/dmd.108.026112. Epub 2009 Feb 5.

PMID:
19196840
11.

Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction.

Bauman JN, Kelly JM, Tripathy S, Zhao SX, Lam WW, Kalgutkar AS, Obach RS.

Chem Res Toxicol. 2009 Feb;22(2):332-40. doi: 10.1021/tx800407w.

PMID:
19161298
12.

Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): structure-activity relationships and strategies for the elimination of reactive metabolite formation.

Walker DP, Bi FC, Kalgutkar AS, Bauman JN, Zhao SX, Soglia JR, Aspnes GE, Kung DW, Klug-McLeod J, Zawistoski MP, McGlynn MA, Oliver R, Dunn M, Li JC, Richter DT, Cooper BA, Kath JC, Hulford CA, Autry CL, Luzzio MJ, Ung EJ, Roberts WG, Bonnette PC, Buckbinder L, Mistry A, Griffor MC, Han S, Guzman-Perez A.

Bioorg Med Chem Lett. 2008 Dec 1;18(23):6071-7. doi: 10.1016/j.bmcl.2008.10.030. Epub 2008 Oct 11.

PMID:
18951788
13.

Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drug.

Bauman JN, Frederick KS, Sawant A, Walsky RL, Cox LM, Obach RS, Kalgutkar AS.

Drug Metab Dispos. 2008 Jun;36(6):1016-29. doi: 10.1124/dmd.108.020545. Epub 2008 Mar 10.

PMID:
18332080
14.

Limited influence of UGT1A1*28 and no effect of UGT2B7*2 polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes.

Peterkin VC, Bauman JN, Goosen TC, Menning L, Man MZ, Paulauskis JD, Williams JA, Myrand SP.

Br J Clin Pharmacol. 2007 Oct;64(4):458-68. Epub 2007 Jun 6.

15.

Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid.

Goosen TC, Bauman JN, Davis JA, Yu C, Hurst SI, Williams JA, Loi CM.

Drug Metab Dispos. 2007 Aug;35(8):1315-24. Epub 2007 Apr 30.

PMID:
17470524
16.

Kinetics of acetaminophen glucuronidation by UDP-glucuronosyltransferases 1A1, 1A6, 1A9 and 2B15. Potential implications in acetaminophen-induced hepatotoxicity.

Mutlib AE, Goosen TC, Bauman JN, Williams JA, Kulkarni S, Kostrubsky S.

Chem Res Toxicol. 2006 May;19(5):701-9.

PMID:
16696573
17.

Udp-glucuronosyltransferase 2b7 is the major enzyme responsible for gemcabene glucuronidation in human liver microsomes.

Bauman JN, Goosen TC, Tugnait M, Peterkin V, Hurst SI, Menning LC, Milad M, Court MH, Williams JA.

Drug Metab Dispos. 2005 Sep;33(9):1349-54. Epub 2005 Jun 24.

PMID:
15980101
18.

The effect of bergamottin on diazepam plasma levels and P450 enzymes in beagle dogs.

Sahi J, Reyner EL, Bauman JN, Gueneva-Boucheva K, Burleigh JE, Thomas VH.

Drug Metab Dispos. 2002 Feb;30(2):135-40.

PMID:
11792681

Supplemental Content

Loading ...
Support Center